Empagliflozin combined with bortezomib in the treatment of heavy and light chain amyloidosis with secondary diabetes: A case report
Abstract
Rationale: Primary heavy and light chain amyloidosis (AHL) is extremely rare globally. This study aimed to report the first clinical treatment of AHL secondary diabetes. We also analyzed fasting blood glucose levels across various treatments. Finally, a reference was provided for treatment and laboratory indicators in AHL with secondary diabetes. Patient concerns: The patient was treated in Department of Hematology in Deyang People’s Hospital. He underwent treatment with daratumumab (DARA) + cyclophosphamide, bortezomib, and dexamethasone (CyBorD), autologous stem cell transplantation and bortezomib for AHL, alongside empagliflozin for blood glucose management. Clinical data and laboratory results were collected during phases of treatment and follow-up. Diagnoses: This patient was a middle-aged man with 2 months of swelling in both lower limbs. Tests, including serum and urine analyses and a kidney biopsy, diagnosed him with AHL (IgA-λ). Interventions: He was diagnosed with diabetes after 4 courses of DARA + CyBorD. Then DARA was discontinued. CyBorD, autologous stem cell transplantation, and bortezomib were continued for AHL, alongside empagliflozin for blood glucose management. Outcomes: Finally, very good partial remission and effective control of blood sugar were obtained. Lessons: Current study presented a case of AHL with secondary diabetes following treatment with DARA + CyBorD. For patients with high fasting blood glucose undergoing targeted therapy or chemotherapy,…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.